Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Securing viral safety for plasma derivatives.

J J Morgenthaler

    Transfusion Medicine Reviews
    |July 27, 2001
    PubMed
    Summary
    This summary is machine-generated.

    This review examines viral safety mechanisms, focusing on inactivation and removal methods for plasma-derived therapeutics. It discusses manufacturing challenges, validation, and emerging threats like prions.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    WHO Expert Committee on Biological Standardization.

    World Health Organization technical report series·2005
    Same author

    New developments in plasma fractionation and virus inactivation.

    Vox sanguinis·2000
    Same author

    Virus inactivation by pepsin treatment at pH 4 of IgG solutions: factors affecting the rate of virus inactivation.

    Transfusion·1996
    Same author

    Effects of intravenous infusion of lipid-free apo A-I in humans.

    Arteriosclerosis, thrombosis, and vascular biology·1996
    Same author

    Cellular processing of copper-67-labeled monoclonal antibody chCE7 by human neuroblastoma cells.

    Cancer research·1995
    Same author

    Internalization and degradation of monoclonal antibody chCE7 by human neuroblastoma cells.

    International journal of cancer·1994

    Area of Science:

    • Biotechnology
    • Pharmaceutical Sciences
    • Virology

    Background:

    • Therapeutics derived from human blood plasma require rigorous viral safety measures.
    • Manufacturing processes for plasma products present unique challenges in ensuring viral clearance.

    Purpose of the Study:

    • To review existing and emerging methods for viral inactivation and removal in plasma-derived therapeutics.
    • To discuss the validation of viral safety and protein integrity.
    • To explore the impact of manufacturing variables and potential new threats like prions.

    Main Methods:

    • Review of current scientific literature on viral safety in plasma therapeutics.
    • Analysis of established viral inactivation and removal techniques.
    • Exploration of novel and experimental methodologies.

    Related Experiment Videos

    Main Results:

    • Established methods effectively reduce viral load, but challenges remain in manufacturing.
    • Validation of both viral safety and therapeutic protein integrity is crucial.
    • Emerging methods show promise for enhanced viral clearance.

    Conclusions:

    • A multi-faceted approach combining inactivation and removal is essential for viral safety.
    • Continuous evaluation of manufacturing processes and emerging threats like prions is necessary.
    • Future research should focus on novel techniques for robust viral clearance.